Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Fulvestrant (ICI 182,780): ER Antagonist in Advanced Breast

    2026-07-21

    Fulvestrant (ICI 182,780): ER Antagonist in Advanced Breast Cancer

    Executive Summary: Fulvestrant (ICI 182,780) is a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM, binding ERα and inducing receptor degradation (APExBIO product info). It specifically downregulates MDM2 protein but not mRNA, shortening MDM2 half-life in ER-positive breast cancer cell lines. Fulvestrant enhances sensitivity to chemotherapies such as doxorubicin, paclitaxel, and etoposide, with evidence of synergistic effects. In vivo, subcutaneous administration reduces tumor growth in xenograft models. Clinical use as a monthly intramuscular injection is well established for advanced ER-positive breast cancer (Wang et al. 2021).

    Biological Rationale

    Estrogen receptors (ERs) are nuclear hormone receptors that mediate the proliferative and survival effects of estrogens in many tissues, including breast epithelium (Wang et al. 2021). In ER-positive breast cancer, aberrant ER signaling drives tumor growth, recurrence, and therapy resistance. Fulvestrant acts by targeting ERα, the predominant isoform implicated in both tumorigenesis and endocrine resistance (see also: Fulvestrant mechanistic insights). This article extends prior reports by detailing post-translational MDM2 regulation and quantifying key in vitro and in vivo benchmarks not previously consolidated.

    Mechanism of Action of Fulvestrant (ICI 182,780)

    Fulvestrant binds ERα with high affinity (IC50 = 9.4 nM), competitively blocking endogenous estrogen binding (APExBIO). Upon binding, it induces conformational changes that target the receptor for proteasomal degradation, leading to rapid ER depletion. This results in downregulation of ER-mediated transcription and protein networks, notably the MDM2 oncoprotein. Unlike transcriptional inhibitors, fulvestrant destabilizes MDM2 post-translationally, reducing its half-life and protein levels without affecting mRNA expression. This multi-level interference with ER signaling and downstream effectors distinguishes fulvestrant from partial antagonists or selective estrogen receptor modulators (SERMs) (advanced mechanistic review).

    Evidence & Benchmarks

    • Fulvestrant (ICI 182,780) binds ERα with an IC50 of 9.4 nM, demonstrating high specificity and potency (product info).
    • MDM2 protein levels are decreased in ER-positive breast cancer cell lines (MCF7, T47D) after fulvestrant treatment, without change in mRNA, indicating post-translational regulation (protocols and benchmarks).
    • Fulvestrant shortens MDM2 half-life and facilitates its proteasomal degradation in vitro (1–10 μM, up to 66 h) (Wang et al. 2021).
    • Combination of fulvestrant with chemotherapeutic agents (doxorubicin, paclitaxel, etoposide) shows synergistic cytotoxicity in ER-positive models (APExBIO).
    • In vivo, subcutaneous administration (5 mg for 4 weeks) in nude mice with human breast cancer xenografts significantly reduces tumor volume (see details).
    • Clinically, fulvestrant is administered as a 250 mg intramuscular injection monthly and is effective in postmenopausal women with advanced ER-positive breast cancer, including after prior endocrine therapy (Wang et al. 2021).

    Applications, Limits & Misconceptions

    Fulvestrant is widely used in endocrine therapy resistance research, apoptosis induction in breast cancer cells, and as a breast cancer chemotherapy sensitizer. Its mechanism targets ERα-driven pathways, making it suitable for ER-positive models and clinical subtypes. The compound is insoluble in water and should be prepared in DMSO or ethanol for in vitro use; DMSO is recommended for stock solutions stored at -20°C (APExBIO).

    Common Pitfalls or Misconceptions

    • Not effective in ER-negative tumors: Fulvestrant's activity is contingent on presence of ERα; it is ineffective in ER-negative breast cancer lines.
    • MDM2 mRNA unaffected: While MDM2 protein is downregulated, mRNA levels remain unchanged, confirming a post-translational effect (protocols and benchmarks).
    • Solubility limitations: Insolubility in water can lead to precipitation or inaccurate dosing unless proper solvents are used for stock preparation.
    • Not a pan-ER antagonist: Fulvestrant primarily antagonizes ERα; effects via ERβ or GPR30 require separate validation (ER subtype roles).
    • Does not restore immune function post-shock: Unlike estradiol, fulvestrant blocks ERα-mediated recovery of splenic CD4+ T cells after hemorrhagic shock (Wang et al. 2021).

    Workflow Integration & Parameters

    Protocol Parameters

    • Stock solution preparation: Dissolve in DMSO at ≥30.35 mg/mL or ethanol at ≥58.9 mg/mL; warm to 37°C or sonicate to enhance solubility (APExBIO).
    • Storage: Store stock at -20°C for several months; avoid repeated freeze-thaw cycles.
    • In vitro concentration: Use 1 μM to 10 μM with incubation times up to 66 hours for ER-positive breast cancer cell lines.
    • In vivo protocol: Administer 5 mg subcutaneously over 4 weeks in mouse xenograft models to achieve significant tumor reduction.
    • Clinical dosing: Monthly intramuscular injection of 250 mg in postmenopausal women with advanced ER-positive breast cancer (Wang et al. 2021).

    Conclusion & Outlook

    Fulvestrant (ICI 182,780) remains a cornerstone for targeting ER signaling in advanced breast cancer, both in laboratory research and clinical protocols. Its ability to induce ERα degradation and modulate post-translational networks such as MDM2 sets it apart from earlier endocrine therapies. The present article consolidates evidence on its mechanistic specificity, dosing, and application boundaries, clarifying misconceptions around its scope. Future studies are expected to refine combinations with chemotherapies and expand protocols for resistance modeling, building upon the robust foundation provided by current mechanistic and clinical data (Wang et al. 2021).

    For further protocol details and advanced mechanistic insights, see this in-depth review, which uniquely integrates immune microenvironment considerations. This article extends prior reports by mapping post-translational MDM2 regulation and workflow parameters, as well as clarifying the specific boundaries of fulvestrant's action compared to estradiol-ERα axis research (see contrast).